B.Med.Sci(Hons), BM. BS. (Hons), Medicinal Science @
University of Nottingham
Dr. Peter Richardson is Chief Medical Officer for Alcon, the eye care division of Novartis. In this role he leads Global Clinical Development, Medical and Regulatory Affairs and Medical Safety. His mission is to build Alcon’s medical and scientific capabilities around the world. To do this he has developed centers of excellence which enable a product pipeline
Dr. Peter Richardson is Chief Medical Officer for Alcon, the eye care division of Novartis. In this role he leads Global Clinical Development, Medical and Regulatory Affairs and Medical Safety. His mission is to build Alcon’s medical and scientific capabilities around the world. To do this he has developed centers of excellence which enable a product pipeline encompassing small molecules, biologics and medical devices. He is focused on meeting the unmet needs of patients and providing medical scientific support for a rapidly growing 10.5 billion USD business.
Peter joined Alcon in 2012 from a role as Chief Scientific Officer at MannKind Corporation, having previously led development organizations for Novartis Pharmacueuticals. He has created world class teams in Switzerland, the UK, North America and Japan, where he was responsible for the successful approval of products in multiple therapeutic areas. He has managed organizational and process change across cultures, continents and capabilities. Since his appointment at Alcon he has successfully built a team of physicians and scientists contributing to multiple product approvals around the world. During his industry career he has managed the successful submission and review of NDAs, sNDAs, BLAs and Marketing Authorization Applications in the US ,Europe and Japan for over 20 marketed products.
He received his undergraduate degree in Medical Science with Honors from the University of Nottingham in the UK and went on to graduate in Medicine from the same university with honors and received the gold medal for medicine. He specialized in internal medicine and endocrinology, gaining membership of the Royal College of Physicians and also earned his Diploma in Pharmaceutical Medicine. His research training was as a Medical Research Council Fellow at the University of Manchester UK. His business training was at Stanford University Graduate School of Business.
Chief Medical Officer @ Global Head of Clinical Development, Medical Affairs, Regulatory Affairs and Medical Safety.
Building organizational capability to support product development and life cycle management for pharmaceuticals, surgical devices and vision care in 5 regions and 75 countries.
Providing over 20 years of leadership and change management experience from key roles in the United States, Europe and Asia. From October 2014 to Present (1 year 3 months) Dallas/Fort Worth AreaHead Global Clinical and Regulatory Affairs @ Global Head of Clinical and Regulatory Affairs. Responsible for ensuring worlwide capabilities in clinical developent and regulatory affairs and establishing a medical affairs organization aligned with a franchise and regional based model. From March 2012 to Present (3 years 10 months) Chief Scientific Officer @ Corporate Vice President responsible for establishing and building development capability for late stage studies of inhaled insulin using novel technology platform. Managed early phase translational medicine programs in cancer immunotherapy and pulmonary delivery of novel peptides. Drove research programs against novel oncology targets and lead successful partnering of prospective candidates with early phase companies. From November 2005 to April 2012 (6 years 6 months) Senior Vice President, Head of Development Japan @ Head of Development Division in Japan. Oversight of clinical, regulatory affairs, exploratory clinical pharmacology, clinical safety, project management, bioanalytics, pre-clinical safety and toxicology, pharmaceutical and chemical development. Member of Executive Committee, Japan and Board of Directors. Member of global Innovation Management Board. Responsible for leading the restructure and revitalization of Japanese organization as part of global pharmaceutical business From 2002 to 2005 (3 years) Tokyo, JapanVice President, Therapueutic Area Head, Clinical Development and Medical Affairs @ Global Therapuetic Area Head covering Arthritis, Bone, Hormone Replacement Therapy, Pulmonary, Gastrointestinal and Dermatology. Responsible for Global Department of 120 physicians and scientists and the development and commercialization of products in the franchise area from phase I through IV. Multiple product approvals US, Europe, Japan and emerging markets, From 1997 to 2005 (8 years) European Head Arthritis, Bone and Respiratory disease @ Therapeutic Area Head for programs in Arthritis and Bone Disease in Basel Switzerland. Established Respiratory Disease Center of Excellence in UK with group of 40 scientists and transferred responsibility respiratory medicine from Switzerland. Lead to successful implementation of global programs for long acting beta 2 agonists in asthma and COPD and development of first monoclonal antibody to IgE. From 1995 to 1997 (2 years)
MRCP(UK), Internal Medicine, Registrar @ The University of Manchester From 1987 to 1991 B.Med.Sci(Hons), BM. BS. (Hons), Medicinal Science @ University of Nottingham From 1978 to 1984 SEP, Business @ Stanford University Graduate School of Business From 1999 to 1999 ECPM, Pharmaceutical Medicine @ Universities of Basel, Strasbourg and Freiburg From 1993 to 1995 Peter Richardson is skilled in: Drug Development, Pharmaceutical Research, Pharmaceutical Development, Corporate Management, Internal Medicine, Team Management, Business Strategy, Biotechnology, CTMS, Clinical Development, Clinical Trials, Drug Discovery, Leadership, Management, Medical Affairs
Looking for a different
Get an email address for anyone on LinkedIn with the ContactOut Chrome extension